Danaher Corporation (DHR)
| Market Cap | 165.08B |
| Revenue (ttm) | 23.74B |
| Net Income (ttm) | 3.89B |
| Shares Out | 722.28M |
| EPS (ttm) | 5.24 |
| PE Ratio | 43.11 |
| Forward PE | 28.55 |
| Dividend | $1.08 (0.47%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 3,954,280 |
| Open | 226.96 |
| Previous Close | 226.16 |
| Day's Range | 225.42 - 230.81 |
| 52-Week Range | 222.53 - 281.70 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 288.00 (+26.01%) |
| Earnings Date | Jan 28, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]
Financial Performance
In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $288.0, which is an increase of 26.01% from the latest price.
News
3 of the Best Companies to Own in 2025 and Beyond
#Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 ...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Danaher Announces Quarterly Dividend
WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common s...
Danaher: A Resilient And Solid Company With Growth Potential
Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduce...
Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vija...
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Revving Up: 2 Underperforming Dividend Giants Ready To Outshine
Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent c...
Understanding Danaher's Cautiousness
Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positi...
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Con...
Danaher beats quarterly profit estimates on strong demand for bioprocessing unit
Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.
Danaher Reports Third Quarter 2024 Results
WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only c...
Cramer's Mad Dash: Danaher
CNBC's Jim Cramer delivers his daily Mad Dash.
3 Dividend Titans With Pricing Power Straight From The Hedge Fund Playbook
Learning from successful hedge funds like Millennium means focusing on minimizing risks. To achieve this, I focus on companies with strong pricing power. They have wide moats and recurring revenue tha...
Danaher Q3 Preview: Market Share Gains In Molecular Testing
I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing ma...
Automated and Closed Cell Therapy Market Research 2024-2029 Featuring Leading Players - Danaher, Thermo Fischer Scientific, Lonza, and Sartorius
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The Ultimate 5: My Highest-Conviction Dividend Stocks
I explore the idea of managing a highly concentrated portfolio and share how I narrowed down my highest-conviction dividend investments to just five stocks. I emphasize the importance of choosing reli...
Danaher Schedules Third Quarter 2024 Earnings Conference Call
WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 202...
The Big 3: ANET, MET, DHR
Today's Big 3 looks at companies trading at or near their 52-week highs but show very different long-term charts. Dan Deming joins Diane King Hall and Ben Lichtenstein to break down the technical tren...
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
BREA, Calif. and TEL AVIV, Israel , Sept.
Danaher Confirms Third Quarter and Full Year 2024 Guidance
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously sched...
Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
WASHINGTON , Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 begin...
Danaher: Lofty Price, Bright Future
Danaher's high valuation and flat 2024 EPS growth might raise eyebrows, but its track record, strategic acquisitions, and long-term growth potential make it a solid buy for those who can. Despite trad...
Betting Big: 3 Dividend Stocks My Family And I Are Buying Aggressively
Market corrections happen under almost every president, and stock performance is not tied to political parties. Currently, inflation remains the key driver of market movements. Focus on undervalued op...